ISSN:
2181-3906
2025
International scientific journal
«MODERN
SCIENCE
АND RESEARCH»
VOLUME 4 / ISSUE 5 / UIF:8.2 / MODERNSCIENCE.UZ
982
MODERN METHODS OF TREATING DIABETES
Sultanov Samadjon
Assistant of the Department of “Pathology and Forensic Medicine”, Central Asian Medical
University
Obidov Dilshodbek Qurbonivich
Central Asian Medical University, 2nd year Pediatrics student, group 823.
dilshodbekobidov419@gmail.com
Yuldashev Abdulhay Abdumutalib o‘g‘li
Central Asian Medical University, 2nd year Pediatrics student, group 823.
Abdullayeva Sadoqat Sharafidinovna
Central Asian Medical University, 2nd year Pediatrics student, group 823.
https://doi.org/10.5281/zenodo.15467329
Abstract. Diabetes mellitus is a chronic metabolic disorder characterized by high blood
glucose levels resulting from defects in insulin secretion, insulin action, or both. Despite the
availability of various therapeutic options, managing diabetes remains a significant challenge
due to disease complexity and the risk of associated complications. Recent advances in diabetes
treatment have introduced novel pharmacological agents, such as sodium-glucose co-transporter
2 inhibitors and glucagon-like peptide-1 receptor agonists, which provide improved glycemic
control and offer cardiovascular and renal protective effects. Additionally, innovations in insulin
delivery systems, including continuous glucose monitoring and artificial pancreas devices, have
enhanced the precision and convenience of insulin therapy. Emerging regenerative medicine
approaches, such as stem cell therapy and islet transplantation, show promising potential for
restoring endogenous insulin production and achieving long-term remission.
Keywords: Insulin therapy, Glycemic control, SGLT2 inhibitors, GLP-1 receptor
agonists, Stem cell therapy.
СОВРЕМЕННЫЕ МЕТОДЫ ЛЕЧЕНИЯ ДИАБЕТА
Аннотация. Сахарный диабет - хроническое метаболическое расстройство,
характеризующееся высоким уровнем глюкозы в крови, возникающим из-за дефектов
секреции инсулина, действия инсулина или того и другого. Несмотря на наличие
различных терапевтических вариантов, управление диабетом остается значительной
проблемой из-за сложности заболевания и риска связанных с ним осложнений. Недавние
достижения в лечении диабета привели к появлению новых фармакологических средств,
таких как ингибиторы натрий-глюкозного котранспортера 2 и агонисты рецепторов
глюкагоноподобного пептида-1, которые обеспечивают улучшенный гликемический
контроль и оказывают сердечно-сосудистое и почечное защитное действие. Кроме того,
инновации в системах доставки инсулина, включая непрерывный мониторинг глюкозы и
искусственные
поджелудочные
железы,
повысили
точность
и
удобство
инсулинотерапии. Новые подходы регенеративной медицины, такие как терапия
стволовыми клетками и трансплантация островков, демонстрируют многообещающий
потенциал для восстановления эндогенной выработки инсулина и достижения
длительной ремиссии.
ISSN:
2181-3906
2025
International scientific journal
«MODERN
SCIENCE
АND RESEARCH»
VOLUME 4 / ISSUE 5 / UIF:8.2 / MODERNSCIENCE.UZ
983
Ключевые слова: Инсулинотерапия, Гликемический контроль, ингибиторы SGLT2,
агонисты рецепторов GLP-1, Терапия стволовыми клетками.
Introduction
Diabetes mellitus is a chronic and complex metabolic disorder that affects millions of
people worldwide. It is characterized by persistent hyperglycemia resulting from defects in
insulin secretion, insulin action, or a combination of both. The disease poses a significant burden
on healthcare systems globally due to its high prevalence and the severe complications it can
cause, such as cardiovascular diseases, neuropathy, nephropathy, and retinopathy. Traditional
treatment approaches, including lifestyle modifications, oral hypoglycemic agents, and insulin
therapy, have been effective in managing blood glucose levels and delaying complications.
However, these conventional methods often face limitations, such as progressive beta-cell
dysfunction, treatment resistance, and patient non-compliance.
As our understanding of the pathophysiology of diabetes deepens, there has been a surge
in the development of innovative therapeutic strategies aimed at addressing these challenges
more effectively.
Recent advances in pharmacology have introduced new classes of drugs that not only
improve glycemic control but also provide additional benefits, including cardiovascular and
renal protection. Moreover, breakthroughs in drug delivery systems, such as continuous insulin
infusion and closed-loop artificial pancreas devices, are revolutionizing how insulin is
administered, making treatments more physiological and convenient. Beyond pharmacotherapy
and delivery mechanisms, regenerative medicine has emerged as a promising frontier, focusing
on restoring the div’s natural ability to produce insulin through stem cell therapy and islet cell
transplantation. Furthermore, the integration of digital health technologies, including
telemedicine, mobile health applications, and wearable glucose monitoring devices, has
transformed patient self-management and enabled real-time personalized care.
Literature review and method
Diabetes mellitus is a chronic metabolic disorder that significantly affects the global
population. Managing this disease requires continuous innovation due to its progressive nature
and complications. Traditional treatments like lifestyle changes, oral medications, and insulin
injections have improved patient outcomes but also have limitations, such as side effects, patient
adherence issues, and the inability to halt disease progression. Recently, numerous advancements
in diabetes care have emerged, aiming to enhance glycemic control, minimize complications, and
improve patients’ quality of life. These innovations encompass new drug classes, improved
insulin delivery methods, regenerative medicine, and digital health technologies. Understanding
these novel approaches is critical for healthcare providers to offer optimal, personalized
treatment. This paper discusses the latest developments in diabetes treatment, emphasizing their
potential to transform diabetes care.
Recent pharmacological advancements have introduced new drug classes that extend
beyond traditional glucose-lowering medications. Sodium-glucose co-transporter 2 inhibitors
(SGLT2 inhibitors) promote glucose excretion through urine and offer cardiovascular and renal
protection benefits.
ISSN:
2181-3906
2025
International scientific journal
«MODERN
SCIENCE
АND RESEARCH»
VOLUME 4 / ISSUE 5 / UIF:8.2 / MODERNSCIENCE.UZ
984
Glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) enhance insulin
secretion, reduce appetite, and contribute to weight loss. Dual and triple receptor agonists are
currently under investigation to target multiple metabolic pathways simultaneously, potentially
improving efficacy and safety. These drugs not only help regulate blood sugar levels but also
reduce risks associated with diabetes, such as heart disease and kidney failure. Additionally,
ongoing research focuses on molecules that modulate inflammation and oxidative stress, which
are key contributors to diabetic complications. The availability of these novel agents provides
clinicians with a wider range of options to customize treatment according to individual patient
needs and comorbidities.
Insulin therapy remains fundamental in managing both type 1 and type 2 diabetes, but
conventional insulin administration often struggles to replicate natural insulin release.
Technological advances have led to continuous subcutaneous insulin infusion via insulin
pumps, which provide more stable and precise insulin dosing. The development of closed-loop
systems, also known as artificial pancreas devices, integrates continuous glucose monitoring
with automated insulin delivery to maintain optimal blood glucose levels with minimal patient
intervention. These systems help reduce hypoglycemia and improve overall glycemic control.
Furthermore, inhaled insulin formulations offer non-invasive alternatives to injections,
enhancing patient comfort and compliance. Research continues into smart insulin formulations
that respond to blood glucose levels dynamically. Collectively, these innovations aim to make
insulin therapy more physiological, flexible, and easier to manage.
Regenerative medicine offers hope for potentially curative treatments for diabetes by
focusing on restoring pancreatic beta-cell function. Stem cell therapy aims to differentiate
pluripotent stem cells into insulin-producing beta cells, which could be transplanted into patients
to restore endogenous insulin production. Islet cell transplantation is already used in some cases
but faces challenges such as immune rejection and limited donor availability. Advances in
immunomodulation seek to prevent autoimmune destruction of beta cells in type 1 diabetes,
enhancing the success of cell-based therapies. Gene editing technologies, like CRISPR, also hold
promise in correcting genetic defects contributing to diabetes. Although still largely
experimental, regenerative therapies represent a paradigm shift from symptom management to
disease reversal, offering long-term solutions and improving patient outcomes significantly.
The integration of digital health tools has revolutionized diabetes care by empowering
patients and healthcare providers with real-time data and improved communication. Wearable
continuous glucose monitors provide detailed glucose trends, helping patients make informed
decisions about diet, activity, and medication. Mobile applications offer tracking, reminders,
educational content, and personalized coaching to support lifestyle modifications. Telemedicine
platforms enable remote consultations, expanding access to specialized care, particularly in
underserved areas. Artificial intelligence algorithms are being developed to predict blood glucose
fluctuations and optimize treatment plans. These technologies enhance patient engagement,
adherence, and early detection of complications. However, challenges such as data privacy, cost,
and digital literacy need addressing to maximize their benefits.
Despite remarkable advancements, several challenges remain in implementing new
diabetes therapies widely.
ISSN:
2181-3906
2025
International scientific journal
«MODERN
SCIENCE
АND RESEARCH»
VOLUME 4 / ISSUE 5 / UIF:8.2 / MODERNSCIENCE.UZ
985
High costs of novel drugs and technologies can limit accessibility, especially in low-
resource settings. Long-term safety and efficacy data are still emerging for many new treatments,
necessitating further clinical trials. Patient education and adherence continue to be critical factors
for successful outcomes. Additionally, healthcare systems must adapt to integrate these
innovations into routine care effectively. Future research is likely to focus on personalized
medicine approaches that tailor treatments based on genetic, environmental, and lifestyle factors.
Combining multiple therapies, including pharmacological, technological, and
regenerative strategies, may offer synergistic benefits. Ethical considerations, regulatory
approvals, and health equity will also shape the future landscape of diabetes management.
The landscape of diabetes treatment is rapidly evolving with the introduction of novel
pharmacological agents, advanced insulin delivery systems, regenerative medicine, and digital
health technologies. These innovations address the limitations of traditional therapies and offer
new hope for improved glycemic control, reduced complications, and enhanced quality of life.
However, successful integration into clinical practice requires overcoming economic,
educational, and systemic barriers. Continued research and multidisciplinary collaboration are
essential to fully realize the potential of these new treatments. Ultimately, a personalized, patient-
centered approach that combines these advances promises to transform diabetes care and
improve outcomes worldwide.
Discussion
The management of diabetes mellitus has significantly evolved over recent years,
reflecting a deeper understanding of the disease’s complex pathophysiology and the need for
more effective and personalized treatments. The introduction of novel pharmacological agents
such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
has not only improved glycemic control but also demonstrated cardiovascular and renal
protective effects. These dual benefits represent a major advancement compared to traditional
glucose-lowering drugs, which primarily focused on blood sugar reduction alone. However,
despite their advantages, these new medications may present challenges such as cost, side
effects, and accessibility, especially in low-income regions, limiting their widespread use.
Advanced insulin delivery systems, including continuous glucose monitors and closed-
loop artificial pancreas devices, have transformed insulin therapy by providing automated and
precise insulin dosing. This technology greatly reduces the risk of hypoglycemia and enhances
patient quality of life by mimicking natural insulin secretion patterns. Nevertheless, issues
related to device affordability, technical complexity, and patient training remain obstacles to
universal adoption. Additionally, the psychological impact of constant monitoring and device
dependence should not be overlooked. Regenerative medicine offers a promising direction for
potentially curative therapies by aiming to restore endogenous insulin production. Stem cell
therapy and islet transplantation, coupled with immunomodulatory strategies, have shown
encouraging results in clinical trials. Nonetheless, challenges such as immune rejection, ethical
concerns, and limited availability of donor cells continue to hinder widespread application.
Further research is necessary to refine these approaches and ensure long-term safety and
efficacy. The rise of digital health technologies has empowered patients and healthcare providers
alike, enabling better self-management and remote monitoring.
ISSN:
2181-3906
2025
International scientific journal
«MODERN
SCIENCE
АND RESEARCH»
VOLUME 4 / ISSUE 5 / UIF:8.2 / MODERNSCIENCE.UZ
986
Mobile apps, wearable sensors, and telemedicine platforms facilitate timely interventions
and personalized care plans. However, disparities in digital literacy, data privacy concerns, and
infrastructure limitations must be addressed to ensure equitable access.
Conclusion
In conclusion, the treatment landscape of diabetes mellitus is undergoing a profound
transformation thanks to the development of innovative therapies. Novel pharmacological agents
offer not only improved glycemic control but also additional protective benefits for the
cardiovascular and renal systems. Advanced insulin delivery technologies provide more
physiological and convenient methods for insulin administration, enhancing patient compliance
and reducing complications. Regenerative medicine holds great promise for restoring natural
insulin production and potentially curing diabetes, although it is still in the experimental stages.
Additionally, digital health technologies have revolutionized disease management by
enabling real-time monitoring and personalized care.
Despite these advancements, challenges such as high costs, accessibility issues, and the
need for extensive patient education remain. To fully realize the benefits of these new treatment
modalities, healthcare systems must focus on improving affordability, training, and
infrastructure. Ultimately, a multidisciplinary, patient-centered approach that integrates
pharmacological innovations, technological advancements, and regenerative therapies offers the
best opportunity to improve outcomes and quality of life for individuals living with diabetes.
Continued research and collaboration are essential to address current limitations and pave
the way for a future where diabetes can be managed more effectively and potentially cured.
REFERENCES
1.
American Diabetes Association. (2024). Pharmacologic approaches to glycemic treatment:
Standards of Medical Care in Diabetes-2024. Diabetes Care, 47(Supplement 1), S98–S110.
2.
Drucker, D. J. (2023). Advances in incretin-based therapies for type 2 diabetes. The Lancet
Diabetes & Endocrinology, 11(3), 211–222.
3.
Shapiro, A. M. J., Lakey, J. R. T., & Ryan, E. A. (2022). Islet transplantation in type 1
diabetes: State of the art and future directions. Diabetes, 71(4), 767–780.
4.
Cefalu, W. T., & Leiter, L. A. (2023). Sodium-glucose cotransporter 2 inhibitors:
Mechanisms and clinical benefits in diabetes management. Nature Reviews Endocrinology,
19(5), 273–287.
5.
Battelino, T., Danne, T., Bergenstal, R. M., & Amiel, S. A. (2023). Artificial pancreas
systems for type 1 diabetes: Current status and future perspectives. Diabetes Technology &
Therapeutics, 25(1), 1–15.
6.
Hermanns, N., & Kulzer, B. (2022). Digital health in diabetes management: Benefits,
challenges and future outlook. Diabetes Research and Clinical Practice, 188, 109900.
7.
Kroon, J., & Jones, P. M. (2024). Stem cell therapy for diabetes: Current progress and
challenges.
Stem
Cells
Translational
Medicine,
13(2),
125–135.
https://doi.org/10.1002/sctm.23-0125
